Skip to Content

FDA E-mails Reveal Apple’s Long Game for Health Tech

Close communications with the agency suggest that Apple is heavily invested in developing medical equipment—but is in no hurry about it.
November 29, 2016
Apple COO Jeff Williams unveiled CareKit earlier this year.

Apple has made no secret of its interest in health care. But e-mails between its executives and the U.S. Food and Drug Administration shed new light on the tech giant’s forays into personal health devices and show that Apple has been taking pains to keep its correspondence with the regulator secret.

The e-mails, obtained by MobiHealthNews via a Freedom of Information Act request, show that Apple has been in regular communication with the FDA over the past three years. A 2013 meeting between the two had previously sparked rumors that the hardware manufacturer was developing medical devices.

In particular, the latest e-mails suggest that Apple has been developing an app for the diagnosis of Parkinson’s disease, as well as some form of cardiac monitoring device.

Apple has already been linked with ways to monitor Parkinson’s as part of its CareKit framework. It has showcased an app by Sage Bionetworks and the University of Rochester, which uses onboard sensors to measure movement, a microphone to perform voice analysis, and on-screen tests to evaluate reactions and dexterity.  

An e-mail from Apple’s Divya Nag to the FDA’s associate director of digital health, Bakul Patel, suggests that the agency may have been actively involved in readying the app. The e-mail describes a meeting arranged to “discuss the telehealth/remote monitoring use case for Parkinson’s and ... the diagnostic app,” adding that the company seeks to understand if “there are any FDA considerations to understand before implementing.”

Elsewhere, an e-mail from Robin Goldstein, then Apple’s principal counsel, to Patel describes a meeting in which the company sought to “talk about two possible (and related) products in the cardiac space, as well as the associated regulatory and quality systems and requirements.”

Those messages probably allude to some kind of wearable device for monitoring heart health. The Apple Watch already contains heart-rate hardware, and startups have already begun developing a medical-grade add-on that could turn it into a device that helps people with serious heart conditions.

Apple’s progress with health-related technology has been slow but steady. After introducing its Apple Health app, the company slowly developed software frameworks that have turned into its CareKit offering—a platform on which researchers can build and test new software.

Tim Cook has previously said that Apple staff “don’t want to put the Watch through the FDA process … because it would hold us back from innovating,” but he has admitted that they “wouldn’t mind putting something adjacent to the watch,” such as an app or some extra piece of hardware, through that process.

It wouldn’t be the only tech giant to be working on medical hardware. Alphabet’s health spin-off Verily has been building a health-tracking watch designed to measure cardiac activity, a prototype of which was seen by MIT Technology Review.

Taken individually, the e-mails between Apple and the FDA don’t reveal a great deal about the tech giant’s health-care plans. But as a whole, they do suggest that Cook and his executives are happy to play a slow, methodical game breaking into the market. Perhaps when they do, they might set some hearts racing.

(Read more: MobiHealthNews, “I Saw Alphabet’s Health Watch,” “The Apple Watch May Be About to Get a Medical-Grade Add-On,” “Apple Hopes You’ll Talk to Your iPhone and Call Your Doctor in the Morning”)

Keep Reading

Most Popular

Rendering of Waterfront Toronto project
Rendering of Waterfront Toronto project

Toronto wants to kill the smart city forever

The city wants to get right what Sidewalk Labs got so wrong.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.